Retatrutide side effects: what the trials actually found

Key takeaways

• It is mostly gut stuff. The most common side effects in the trials were gastrointestinal: nausea, diarrhea, vomiting, and constipation .
• Mostly mild to moderate, mostly early. The gut effects were dose-related and mostly mild to moderate, eased with a lower starting dose , and clustered during the dose-escalation period .
• More dose, more nausea. A meta-analysis of three trials (878 people) found nausea roughly four times as likely as placebo at the top doses, with vomiting rising even more steeply with dose .
• Some people quit over it. Adverse events drove 6 to 16 percent of retatrutide participants to stop in Phase 2 (versus none on placebo), and about 11 percent stopped the 12 mg dose in the Phase 3 TRIUMPH-1 trial .
• Not all gut: heart rate ticked up. The trials saw a dose-dependent rise in heart rate that peaked around 24 weeks and then declined . Retatrutide is still investigational, not approved.

What the trials actually logged

Here is the trial-measured profile, plain. These are the effects the studies tracked in supervised patients on a slow dose ramp, which is worth holding in mind before the forum section below.

The gut stuff, and why the first months are the worst of it

The headline is simple: retatrutide's side effects are mostly digestive. The big four are nausea, diarrhea, constipation, and vomiting, with nausea the one people report most . None of that is a surprise for this drug class. Slowing the stomach down is part of how these drugs cut appetite, and a slower stomach is a queasier one.

The timing is the useful part. In the trials these effects were dose-related and mostly mild to moderate , and they clustered while the dose was being raised, per Lilly's summary of the trial, then settled . That is why the trials started low and stepped up slowly: a lower starting dose took the edge off . The rougher stretch tends to be the climb, not the cruise.

How rough it gets tracks the dose. A 2025 meta-analysis pooling three trials and 878 people found nausea about four times as likely as placebo at the higher doses, and vomiting climbing even faster, though the pooled group was small and the error bars were wide . Read it as a clear direction (more dose, more gut), not a precise personal percentage.

How many people quit over it

The honest measure of how bad side effects are is how many people walk away. In Phase 2, adverse events led 6 to 16 percent of retatrutide participants to stop the drug, against none on placebo . In the 2026 Phase 3 TRIUMPH-1 readout (a maker topline), about 11 percent stopped the top 12 mg dose, versus about 5 percent on placebo .

The one that is not your gut: heart rate

The side effect people forget is cardiac, and it is mild but worth naming. The trials saw a dose-dependent rise in heart rate that peaked around 24 weeks and then declined over the back half of the study . A small resting-pulse bump is a known feature of this drug class, not a retatrutide quirk.

It is not a reason to panic, and it is not a reason to ignore it either. It is the clearest example of why the trial setting mattered: people were monitored while it happened. That context does not come in a gray-market vial.

Trial data and forum posts are not the same thing

Search retatrutide side effects and you will find a wall of firsthand stories: the brutal first week, the sulfur burps, the day the nausea finally lifted. A lot of it rings true, and it tends to echo the trial pattern, which is mostly gut and mostly early. That overlap is reassuring. It is also where people get the wrong idea.

• Posts are self-reported, not measured. A forum is not a trial. People who had a rough time post more, and nobody is counting the quiet majority, so the online mix of effects is not the real rate of anything.
• The sample is skewed. The people posting bought retatrutide outside a trial, often from gray-market research-chemical channels, without the slow titration, dosing checks, and monitoring that kept the trial side effects manageable.
• A bad batch reads like a side effect. With unregulated product, an underdosed, overdosed, or contaminated vial can produce symptoms that look like drug effects but are really quality problems. The trial data does not carry that noise.
• Use forums for the human texture, not the numbers. They are great for what the rough week feels like and what helped. They are not a source for how likely anything is. For that, the trials are the only honest answer, and we do not cite forum threads as evidence.

The honest bottom line

Retatrutide's side effects, as the trials measured them, are mostly digestive, mostly mild to moderate, mostly front-loaded into the dose-climb, and steeper at higher doses, where more people quit. A modest heart-rate bump rounds it out. That is the real profile, and it is the same shape as the rest of this drug class, just attached to the strongest weight-loss numbers so far.

And the part the trials cannot tell you: retatrutide is still investigational, not an approved medicine, so anything sourced outside a trial skips the supervision that made that profile look as clean as it did. The side effects are manageable on paper. On paper assumes the dose ladder and the oversight came with it.

For research and educational purposes only. Not medical advice.

pepSmart has not commissioned independent clinical review of this article.

More on how we write and source these pieces: Editorial process and contributor disclosure and Sourcing posture.

Spot an error? Email corrections via /about.

Sources: 5 entries, primary canon (the NEJM Phase 2 trial and a 2025 peer-reviewed meta-analysis) plus reputable secondary sources with inline acknowledgment (an independent CME summary of the trial and Lilly's industry-funded Phase 2 and Phase 3 releases), last reviewed 2026-06-06.

Related tools

• Tirzepatide dose calculator - Run tirzepatide-focused vial draw math.
• GLP-1 conversion calculator - Convert a GLP-1 mg dose to U-100 units and ml.
• GLP-1 ramp planner - Preview a linear educational dose-step table.
• Peptide half-life calculator - Estimate single-dose decay from cited half-life constants.
• PK simulator overview - Public overview of the Pro pharmacokinetic simulator.